VEGA

Phase 2a randomized, double-blind, active controlled, parallel-group, multicenter, proof of concept clinical study to evaluate the efficacy and safety of combination therapy with Guselkumab (Tremfya) and Golimumab (Simponi) in participants with moderately to severely active Ulcerative Colitis.

Sponsor: Janssen Research & Development

Principal Investigator: Dr. William Holderman

We are looking for patients to participate in this study:

  • Naive to TNF antagonists
  • Moderate to severe Ulcerative Colitis diagnosed more than 3 months
  • Age 18 to 65
  • Failure from previous treatment with 6-MP, 5ASA, prednisone or had inadequate response with, lost response to, or was intolerant to immunomodulators or other biologics, or corticosteroid dependent
  • No history of tuberculosis